CLINICAL TRIAL: CREATINE IN SUBJECTS WITH TREATED PARKINSON'S DISEASE (PD)

临床试验:肌酸治疗帕金森病 (PD) 患者

基本信息

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The main study will evaluate whether the investigational drug Creatine is able to slow the progression of Parkinson's Disease (PD). The research hypothesis is that the group being treated with Creatine will show less disease progression by 5 years than the group on placebo as evaluated by a Global Statistical Test comprised of generally measured PD functioning: ambulatory capacity, cognitive impairment, and global functioning. Secondary specific aims are to compare the Creatine and placebo groups on additional measures of efficacy, safety, and tolerability using data between baseline and 5 years follow up. Within the NET-PD LS-1 a sub-study is being conducted for blood sample collection to obtain and store DNA for future PD/and neurological disease research. The blood collection for DNA sampling is a one time blood draw taking at the screening/baseline visit of consenting participants. Procedures involving human subjects will be conducted during clinical visit of which there will be at least 9 during the 5 year study. After the second year there will be at least three telephone contacts to review side effects, medications, health provide visits, and a study medication questionnaire. The most extensive clinical will comprise of the following: Personal and Family Medical History, Vital Signs (pulse, blood pressure, weight), Activities of Daily Living, Overall Functioning Questionnaire, Thinking Ability Test, Memory Test, Depression Scale (Beck Depression Inventory), Blood and urine testing (1 Tbs. of blood will be collected for routine testing), Pregnancy test for qualifying individuals, Parkinson's exam, and ECG will be performed at three visits on a subset of enrolled participants. In addition to the clinical procedures, questionnaires performed during telephone calls will again be administered during visits to the clinic.
这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者(PI)可能从另一个NIH来源获得了主要资金, 因此可以在其他CRISP条目中表示。所列机构为 研究中心,而研究中心不一定是研究者所在的机构。 主要研究将评估研究药物肌酸是否能够减缓帕金森病(PD)的进展。 研究假设是,通过由一般测量的PD功能(步行能力、认知障碍和整体功能)组成的整体统计检验评价,肌酸治疗组在5年内的疾病进展将低于安慰剂组。 次要具体目的是使用基线和5年随访之间的数据比较肌酸组和安慰剂组的疗效、安全性和耐受性的其他指标。 在NET-PD LS-1中,正在进行一项血液样本采集子研究,以获得和储存DNA,用于未来的PD/和神经系统疾病研究。 用于DNA采样的血液采集是在知情同意的受试者的筛选/基线访视时进行的一次性抽血。 涉及人类受试者的程序将在临床访视期间进行,在5年研究期间将至少进行9次。第二年后,将至少进行三次电话联系,以审查副作用、药物、健康提供访视和研究药物问卷。 最广泛的临床将包括以下内容:个人和家族病史、生命体征(脉搏、血压、体重)、日常生活活动、总体功能问卷、思维能力测试、记忆测试、抑郁量表(贝克抑郁量表)、血液和尿液检测(1 Tbs.将在三次访视时对一部分入组受试者进行合格个体的妊娠试验、帕金森病检查和ECG。 除临床程序外,在门诊访视期间将再次进行电话访视期间进行的问卷调查。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROBERT W HAMILL其他文献

ROBERT W HAMILL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROBERT W HAMILL', 18)}}的其他基金

CLINICAL TRIAL: CREATINE IN SUBJECTS WITH TREATED PARKINSON'S DISEASE (PD)
临床试验:肌酸治疗帕金森病 (PD) 患者
  • 批准号:
    8166974
  • 财政年份:
    2010
  • 资助金额:
    $ 4.48万
  • 项目类别:
DNA REPOSITORY FOR PATIENTS WITH PARKINSON'S DISEASE
帕金森病患者 DNA 存储库
  • 批准号:
    7378597
  • 财政年份:
    2006
  • 资助金额:
    $ 4.48万
  • 项目类别:
MINOCYCLINE AMP; CREATINE IN EARLY UNTREATED PARKINSON'S DISEASE
米诺环素安培;
  • 批准号:
    7378573
  • 财政年份:
    2006
  • 资助金额:
    $ 4.48万
  • 项目类别:
MULTICENTER STUDY OF COQ10 & GPI 1485 IN EARLY UNTREATED PARKINSON'S DISEASE
COQ10 的多中心研究
  • 批准号:
    7378581
  • 财政年份:
    2006
  • 资助金额:
    $ 4.48万
  • 项目类别:
MULTICENTER STUDY OF COQ10 & GPI 1485 IN EARLY UNTREATED PARKINSON'S DISEASE
COQ10 的多中心研究
  • 批准号:
    7206965
  • 财政年份:
    2005
  • 资助金额:
    $ 4.48万
  • 项目类别:
DNA REPOSITORY FOR PATIENTS WITH PARKINSON'S DISEASE
帕金森病患者 DNA 存储库
  • 批准号:
    7206975
  • 财政年份:
    2005
  • 资助金额:
    $ 4.48万
  • 项目类别:
MINOCYCLINE & CREATINE IN EARLY UNTREATED PARKINSON'S DISEASE
米诺环素
  • 批准号:
    7206950
  • 财政年份:
    2005
  • 资助金额:
    $ 4.48万
  • 项目类别:
Minocycline & Creatine in early untreated Parkinson's Disease
米诺环素
  • 批准号:
    7041563
  • 财政年份:
    2004
  • 资助金额:
    $ 4.48万
  • 项目类别:
Multicenter Study of CoQ10 & GPI 1485 in Early Untreated Parkinson's Disease
CoQ10 的多中心研究
  • 批准号:
    7041573
  • 财政年份:
    2004
  • 资助金额:
    $ 4.48万
  • 项目类别:
Parkinson Disease Neuroprotection Clinical Trial
帕金森病神经保护临床试验
  • 批准号:
    6797312
  • 财政年份:
    2002
  • 资助金额:
    $ 4.48万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 4.48万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 4.48万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 4.48万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 4.48万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 4.48万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 4.48万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 4.48万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 4.48万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 4.48万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 4.48万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了